
==== Front
eBioMedicine
EBioMedicine
eBioMedicine
2352-3964
Elsevier

S2352-3964(24)00319-0
10.1016/j.ebiom.2024.105283
105283
Articles
Regulator of G-protein signaling expression in human intestinal enteroendocrine cells and potential role in satiety hormone secretion in health and obesity
McRae Alison N. a
Ticho Alexander L. a
Liu Yuanhang b
Ricardo-Silgado Maria Laura a
Mangena Nothando N. a
Jassir Fauzi Feris a
Gonzalez-Izundegui Daniel a
Calderon Gerardo a
Rohakhtar Fariborz Rakhshan c
Simon Vernadette c
Li Ying b
Leggett Cadman d
Hurtado Daniela e
LaRusso Nicholas d
Acosta Andres J. acosta.andres@mayo.edu
a∗
a Precision Medicine for Obesity Program and Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
b Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
c Center for Individualized Medicine (CIM), Mayo Clinic, Rochester, MN, USA
d Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
e Division of Endocrinology, Diabetes, Metabolism, and Nutrition Mayo Clinic, Jacksonville, FL, USA
∗ Corresponding author. Precision Medicine for Obesity Program and Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. S.W., Rochester, MN, 55905, USA. acosta.andres@mayo.edu
13 8 2024
9 2024
13 8 2024
107 1052832 3 2023
30 7 2024
31 7 2024
© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Summary

Background

Gut L-type enteroendocrine cells (EECs) are intestinal chemosensory cells that secrete satiety hormones GLP-1 and PYY in response to activation of G-protein coupled receptors (GPCRs) by luminal components of nutrient digestion and microbial fermentation. Regulator of G-protein Signaling (RGS) proteins are negative regulators of GPCR signaling. The expression profile of RGS in EECs, and their potential role in satiety hormone secretion and obesity is unknown.

Methods

Transcriptomic profiling of RGS was completed in native colonic EECs was completed using single-cell RNA sequencing (scRNA-Seq) in lean and obesity, and human jejunal EECs with data obtained from a publicly available RNAseq dataset (GSE114853). RGS validation studies were completed using whole mucosal intestinal tissue obtained during endoscopy in 61 patients (n = 42 OB, n = 19 Lean); a subset of patients’ postprandial plasma was assayed for GLP-1 and PYY. Ex vivo human intestinal cultures and in vitro NCI–H716 cells overexpressing RGS9 were exposed to GLP-1 secretagogues in conjunction with a nonselective RGS-inhibitor and assayed for GLP-1 secretion.

Findings

Transcriptomic profiling of colonic and jejunal enteroendocrine cells revealed a unique RGS expression profile in EECs, and further within GLP-1+ L-type EECs. In obesity the RGS expression profile was altered in colonic EECs. Human gut RGS9 expression correlated positively with BMI and negatively with postprandial GLP-1 and PYY. RGS inhibition in human intestinal cultures increased GLP-1 release from EECs ex vivo. NCI–H716 cells overexpressing RGS9 displayed defective nutrient-stimulated GLP-1 secretion.

Interpretation

This study introduces the expression profile of RGS in human EECs, alterations in obesity, and suggests a role for RGS proteins as modulators of GLP-1 and PYY secretion from intestinal EECs.

Funding

AA is supported by the NIH(C-Sig P30DK84567, K23 DK114460), a Pilot Award from the Mayo Clinic Center for Biomedical Discovery, and a Translational Product Development Fund from The Mayo Clinic Center for Clinical and Translational Science Office of Translational Practice in partnership with the 10.13039/100018188 University of Minnesota Clinical and Translational Science Institute .

Keywords

scRNA-Seq
Obesity
GLP-1
PYY
Enteroendocrine cells
L-cells
RGS
==== Body
pmc Research in context

Evidence before this study

Hormone-secreting gut enteroendocrine cells (EECs) are specialized for luminal sensing and express nutrient-activated GPCRs. Activation of these receptors by ingested nutrients results in secretion of enteroendocrine hormones such as GLP-1 and PYY, regulating appetite, food intake, and glucose homeostasis. Regulator of G-protein Signaling (RGS) proteins represent a major mechanism for the negative regulation of GPCR signaling. Tissue-specific expression of RGS is essential to the regulation of various critical processes, many already well established in the cardiovascular, immune, and central nervous system. However, there are no published studies describing the expression profile of the RGS family in human EECs, and the role RGS may play in EEC functionality and its aberrations in disease states like obesity remains unknown.

Added value of this study

Transcriptomic profiling of human colonic EECs using scRNAseq, and analysis of a jejunal EEC transcriptomic database identified expression of the RGS family in EECs, and further revealed an altered colonic EEC RGS transcriptomic landscape in obesity. In EECs, RGS, specifically RGS9, may modulate the secretion of nutrient-stimulated GPCR-mediated GLP-1 and PYY from gut L cells, and this system may serve as a potential target for the pharmacological treatment of obesity.

Implications of all the available evidence

Many pharmacological attempts have been made to simulate the physiological effects of L-cell satiety hormone peptides GLP-1 and PYY as a treatment for obesity. Targeting EEC-specific RGS proteins may present new beneficial applications to therapeutic strategies in GPCR-based drug discovery for obesity. A pharmacological approach to stimulating maximal endogenous secretion of satiety hormones may include the combination of GPCR-agonists coupled with EEC-specific RGS-inhibitors.

Introduction

Enteroendocrine cells (EECs) are rare hormone-secreting cells sparsely distributed throughout the length of the gastrointestinal (GI) tract, representing approximately 1% of the gut mucosal population.1 Collectively, EECs constitute the largest endocrine system in the body, and play a major role in the regulation of metabolic homeostasis. Intestinal EECs are specialized for sensing the GI luminal environment and secrete over 20 hormones in response to luminal factors to influence gastrointestinal secretion and motility, regulate food intake, and glucose homeostasis.1 Traditional hormone-based classifications of EECs generally delineate eight distinct subtypes based on their localization along the GI tract, and hormone secretory profile.2 However a growing body of evidence suggests the existence of both heterogeneity and plasticity of EEC hormone secretory profiles, and the traditional classification may soon require updating.3,4 To sense the wide range of potential luminal stimuli, EECs express a diverse variety of sensory mechanisms, including G-protein-coupled receptors (GPCRs), nutrient transporters, and ion channels.5 The classically define L-type EECs are most abundant in the ileum and colon and predominately secrete satiety-inducing hormones glucagon-like peptide 1 (GLP-1) and peptide-YY3-36 (PYY) after a meal in response to activation of their surface GPCRs by luminal components of nutrient digestion and microbial fermentation, which function to retard gastric and small bowel transit, maintain glucose homeostasis, and reduce food intake and appetite.6,7

The systemic impact of EEC-secreted gut hormones on control of food intake, appetite, and glucose homeostasis has led to considerable investigation into their role in the pathogenesis and treatment of metabolic disorders including obesity.1 In previous studies, levels of satiety hormones GLP-1 and PYY have been found to be lower in obesity compared to normal weight controls, increased 10-fold after bariatric surgery, and decreased with diet-induced weight loss.8, 9, 10, 11, 12, 13 Gut satiety hormones additionally represent powerful therapeutic targets. Indeed, long-acting GLP-1 analogs are available clinically for treatment of T2D and obesity.14 Furthermore, stimulation of endogenous secretion from EECs using small molecule GPCR-agonists represents an appealing therapeutic strategy for these and other metabolic disorders.

In EECs, activation of chemosensory GPCRs and their downstream effectors orchestrate metabolism, digestion, and food intake. In other tissues, GPCR signaling is tightly regulated by various mechanisms. Regulator of G-protein Signaling (RGS) proteins, a family of 20 canonical proteins that serve as key negative regulators of GPCR signaling, function as GTPase-activating proteins (GAPs) to heterotrimeric G-proteins, leading to the rapid termination of G-protein signaling.15 Tissue-specific expression of RGS is essential to the regulation of various critical processes, many already well established in the cardiovascular, immune, and central nervous system.16, 17, 18 As RGS proteins represent a major mechanism for the negative regulation of GPCR signaling, we hypothesized that EECs, which heavily rely on GPCR signaling to carry out their main luminal sensing functionality, also employ RGS proteins to coordinate GPCR activation and deactivation within the cell. However, there are no published studies describing the expression profile or function of the RGS family in human EECs.

In the current study, we aimed to establish the RGS expression profile of native human intestinal EECs, describe alterations to their transcriptional landscape in obesity, and further explore the physiological role of RGS in GPCR-mediated secretion of GLP-1 from EECs and the functional consequence of its dysregulation.

Methods

Participants, tissue collection and hormone testing

The study was approved by the Mayo Clinic Institutional Review Board, and all participants gave written informed consent following thorough explanation of the study details. Studies were performed at the Mayo Clinic Clinical Research Trials Unit (CRTU) after an 8-h fasting period. Endoscopic mucosal tissue was collected from a total of 61 participants (lean n = 19; obesity n = 42) after receiving a tap water enema during a flexible sigmoidoscopy, or during routine colonoscopy with ileal intubation (Table 1, “Complete Cohort”). During the procedure, 8–16 mucosal biopsies were obtained from the colon and/or ileum. Tissue was then processed for appropriate downstream applications, as described below.Table 1 Patient Demographics for complete cohort and subcohorts: scRNA-Seq discovery cohort and validation cohort.

Cohort	Parameter	Lean	Obesity	p-value	
Complete cohort	N	19	42		
	Age (years)	39 ± 13.1	43 ± 11.7	0.26	
	Female N (%)	11 (58)	25 (60)		
	BMI (kg/m2)	23.1 ± 1.9	39.9 ± 6.9	0.0001	
scRNA-Seqa	N	4	5	–	
	Age (years)	28 ± 1.4	44 ± 4.9	0.001	
	Female N (%)	3 (75)	4 (80)	–	
	BMI (kg/m2)	23.0 ± 2.9	35.4 ± 2.1	0.0001	
Colonic RGS hormone associationsa	N	16	31	–	
	Age (years)	40 ± 13.2	39 ± 9.9	0.84	
	Female N (%)	9 (56)	20 (65)	–	
	BMI (kg/m2)	23.2 ± 1.6	41.4 ± 7.0	0.0001	
Validation: single-cell RGS family tissue validationb	N	6	9	–	
Age (years)	53 ± 4.0	58 ± 4.7	0.06	
	Female N (%)	3 (50)	3 (33)	–	
	BMI (kg/m2)	23.7 ± 1.0	35.5 ± 5.0	0.0001	
Data reported as Mean ± SD.

Significance testing used an un-paired student t-test. Significant difference between lean and obesity.

a Denotes studies where colonic biopsies only were collected.

b Denotes studies where both colonic and ileal biopsies were collected.

For determination of plasma postprandial GLP-1 and PYY, participants received a mixture of 63 g glucose in 240 ml of skim milk and a meal with 2 scrambled eggs, 50 g of Canadian Bacon and one slice of bread (∼560 Kcal: 43% carbohydrate, 18% protein, and 40% fat). Plasma samples were collected fasting and postprandial at 15, 45 and 90 min for measurement of GLP-1 (Cat#GLP1T-36HK, Millipore Sigma), and PYY (Cat#PYYT-66HK, Millipore Sigma).

Single-cell RNA-sequencing and analysis

Tissue collection and cryopreservation and FACS-isolation

Mucosal biopsies from the sigmoid colon were collected, cryopreserved, and prepared for scRNA-Seq using FACS-isolation of single, live non-apoptotic cells as previously described.19

scRNA-Seq and data analysis

We performed all steps following the Chromium 10X Genomics single cell RNA-Sequencing (scRNA-Seq) platform, with a targeted cell capture of 10,000 single cells. We used the Chromium Single Cell 3′ Library & Gel Bead Kit v2 (10X Genomics). In short, all samples and reagents were prepared and loaded into the chip. Then, we ran the Chromium Controller for droplet generation. Reverse transcription was conducted in the droplets. We recovered cDNA through demulsification and bead purification. Pre-amplified cDNA was further subjected to library preparation. Libraries were sequenced on an Illumina Hiseq 4000 for 100 paired-end runs at 1 sample over 2 lanes.

We used 10X Genomics Cellranger Single Cell Software Suite (v3.0.0) to generate FASTQ files, perform alignment to hg38 reference genome, filtering, barcode counting and UMI counting. For subsequent clustering (k-means) and data analysis, we followed the integrated analysis workflow in the Seurat package (v3.1) (https://satijalab.org/seurat/v3.1/integration.html). Genes that were expressed in fewer than 3 cells, cells that expressed fewer than 200 genes and >40% mitochondria genes were excluded for downstream analysis in each sample. Each dataset was normalized using log normalization and scaled for each gene across all cells. All datasets were integrated, scaled, and clustered on the low-dimensional space. Resolution parameter for Seurat was set to 0.3 for all data integrations. Enriched gene markers in each cluster conserved across two conditions were identified with fold change larger than 2, adjusted p-value smaller than 0.05 in both conditions. All clustering and statistical analysis was performed in R (v 3.5.2). Raw count gene expression data from scRNAseq were normalized using Trimmed Mean of M-values (TMM) method from edgeR and converted to transcript per million (TPM).20 Cells were categorized into three groups based on the gene expression levels of GCG: 1). Cells with positive expression for GCG in the Enteroendocrine cluster 15; 2) Cells with no expression for GCG in the enteroendocrine cluster 15; 3) Cells in other clusters. Average gene expression levels were computed for each group.

Analysis of GSE114853 RNA-sequencing database

Data acquisition and analysis

The “Human enteroendocrine cell transcriptomic profiling” GSE114853 RNAseq dataset and their associated information were obtained from the NCBI Gene Expression Omnibus (GEO). Methodology for the comparative transcriptomic study is fully described as previously published.21 Briefly, transcriptomic profiling of 3 cell populations of human jejunum in 11 participants was completed by bulk RNAseq using Illumina HiSeq 4000. The three cell populations included FACS-purified populations of human jejunal enteroendocrine cells: L-type jejunal EECs (GLP1+/CHGA+/SCG2+), non-L-type jejunal EECs (GLP1-/CHGA+/SCG2+), and the third population contained non-EEC jejunal cells (GLP1-/CHGA-/SCG2-). The raw count gene expression data were then normalized using TMM method from. EdgeR and converted to transcript per million (TPM).20 Average gene expression levels were computed for each of the three groups.

Enteroendocrine physiology validation studies

Participants

We interrogated the gut hormone expression profile of 47 participants (Table 1, “Colonic RGS Hormone Associations”)within our studies for either mucosal mRNA and protein expression, plasma hormone levels, or both. In a cohort of 15 participants both colonic and ileal biopsies were collected for validation of RGS expression (Table 1, “Validation: Single-cell RGS family tissue validation”). Colonic and ileal mucosal biopsies, as well as postprandial plasma samples were collected as described above. Colonic and ileal mucosal biopsies were either immediately cryopreserved, placed in RNAlater (Ambion) for subsequent RT-qPCR, or fixed in 10% NBF for immunofluorescence studies.

Traditional RT-qPCR

Total RNA was extracted from RNAlater preserved biopsies using the RNeasy Plus Micro Kit (Cat#74034, Qiagen), reverse transcribed into cDNA using the AffinityScript QPCR cDNA Synthesis Kit (Cat#600559, Agilent Technologies), and amplified by real-time quantitative PCR using gene-specific primers (250 nM final concentration; Supplemental Table S1) and performed in the LightCycler 480 II System (Roche Life Sciences) using SYBR green (Cat#172-5270, Bio-Rad) detection. Eukaryotic Elongation Factor 2 (EEF2) was used as an endogenous control.22,23 Gene expression was calculated using the 2-ΔΔCt method and presented as normalized gene expression to EEF2 expression for each sample.

Immunofluorescence

Human mucosal colonic biopsies were fixed in 10% NBF overnight. The fixed tissue was incubated in 70% ethanol for 48 h and stored in sterile PBS at 4 °C until embedding. Tissue was embedded in paraffin and slides containing 5 μm FFPE sections were prepared. The sections were deparaffinized and rehydrated through a graded alcohol series, followed by antigen unmasking (Cat#H-3300-250, Vector Laboratories). Tissue was permeabilized with 0.1% Triton X-100 and then blocked with 10% FBS, 1% BSA, 0.1% Tween-20 in PBS for 1 h at room temperature. Sections were probed with primary antibodies, followed by incubation with fluorochrome conjugated secondary antibodies to detect respective primary antibodies. A negative control and a no primary antibody control was used for each antibody. Antibodies used are described in the Supplementary Materials. Slides were mounted with ProLong™ Gold Antifade Mountant with DAPI (Cat#P3693, Life Technologies). Images were taken on a Confocal Microscope (LSM 980 Axio Observer), and probes were excited using 405, 488, and 633 nm laser lines. Resulting images were analyzed with the ZEN software (ZEN 2.1, Zeiss).

Generation of primary cultures from human intestinal biopsies

Primary culture of intestinal monolayers, originating from human colon and ileum were generated using previously reported methodologies.24,25 Aliquots (100 μl) were plated into 96-well plates coated with 4 mg/ml Matrigel, and primary cultures were incubated for 4-h at 37 °C in 5% CO2.

NCI–H716 general cell maintenance

The Human L cell line NCI–H716 was obtained from the American Type Culture.

Collection (CCL-251, ATCC) and maintained at a density of ∼500,000 cells/ml in suspension culture in T25 suspension flasks (5669-0195, USA Scientific) containing RPMI medium (25–506, GenClone) supplemented with 10% FBS, 100 IU/ml penicillin, and 100 μg/ml streptomycin. Cells were kept at 37 °C, 5% CO2, until 85% confluent, then split 1:5 and transferred to fresh T25 flasks.

Transfection of NCI–H716 cells and generation of stable expressing RGS9 NCI–H716 cells

NCI–H716 cells were cultured in RPMI-1640 medium with 10% (v/v) FBS and grown at 37 °C in 5% CO2. A RGS9 construct containing human RGS9-2 (accession number NM_001081955.3) in pcDNA 3.1 expression vector was purchased form GenScript (Clone ID: OHu05606). Transfection of NCI–H716 cells was performed using Lipofectamine 3000 (Invitrogen) following manufacturer's instructions and selected with Geneticin G418 (100 μg/ml, Gibco).

NCI–H716 enteroendocrine differentiation

NCI–H716 cells were split into 96-well plates pre-coated with 150 μl per well 4 mg/ml matrigel (354234, Corning), at a density of 100,000 cells per well in 200 μl media containing high glucose DMEM (11965092, Gibco) supplemented with 10% (v/v) FBS, 100 IU/ml penicillin, and 100 μg/ml streptomycin. Cells were maintained for 48 h to allow for enteroendocrine differentiation.

RGS inhibition cell culture experiments

Primary human intestinal cultures were washed with Dulbecco's Phosphate-Buffered Saline (DPBS, Cat#21-030-CV, Corning) and exposed to treatments (200 μl, n = 6 wells/treatment) for 2-h. Treatments included: varying doses of RGS-inhibitor CCG-50014 (Cat#10802, Cayman Chemical) alone, or stimulating GPCR-agonists: meat hydrosylate (2% w/v; Cat#70174, Sigma), 1,10-Phenanthroline (500 μM; Cat#131377, Sigma), Sodium Acetate/Propionate (500 μM each; Cat#S8750, P5436, Sigma), taurocholic acid (500 μM; CAT#T4009, Sigma).26, 27, 28, 29 All treatments were prepared in DPBS-0.5% BSA (w/v) control media. CCG-50014 inhibitor dosage range was based on dosages previously described to effectively attenuate RGS activity in RGS14 and RGS10 proteins, members of the R12 RGS protein family, most closely related to the R7 RGS family, which includes RGS9.30 Cells were incubated at 37 °C for 2 h, after which media was collected and centrifuged (5 min, 1000×g, 4 °C) to pellet any cells, and the supernatant was then frozen at −20 °C for subsequent ELISA analysis. Cell viability was measured using the Trypan Blue exclusion test. The active GLP-1 concentration of the media supernatants was determined by ELISA (Cat#EZGLPHS-35 K, EMD Millipore Sigma) according to manufacturer instructions. Active GLP-1 levels were expressed as fold to their respective controls.

Differentiated NCI–H716 cells were thoroughly washed with DPBS and treated for 2 h with DPBS containing 0.5% BSA and either 1) vehicle (1:1000 DMSO and 1:1000 EtOH), CCG-50014 (25 μM), 1,10-phenanthroline (1 mM), or CCG-50014 (25 μM) and 1,10-phenanthroline (1 mM). Samples were processed as above.

Ethics statement

This study was approved by The Mayo Clinic Institutional Review Board (IRB), Rochester, MN, United States (Protocol numbers: 17-009999, 17-009678, 16-007060,16-008664). All authors had access to the full data, reviewed and revised the manuscript, and gave approval to submit the manuscript for publication.

Statistics

Data are expressed as mean ± SD unless otherwise stated. Data for differential gene expression in the RNA sequencing datasets were analyzed using the default Seurat package settings, based on the non-parametric Wilcoxon rank sum test. Graphical data from the RNA sequencing datasets are visualized as bar charts, where top horizontal line of bar represents average expression or proportion, and further denoted with exact numbers above individual bars. The nonparametric Spearman correlation analysis was completed to measure the associations between RGS expression and BMI, human plasma PYY AUC and GLP-1 AUC, and fasting colonic PYY and GCG mRNA expression. Data for nonparametric correlations are expressed as Spearman correlation coefficients (r) and 95% confidence interval (CI), with accompanying regression lines fitted with ordinary least squares. Significance testing comparing groups for relative RGS levels, normalized GLP-1 cell secretion from human intestinal cultures ex vivo and NCI–H716 cells in vitro, used a two-tailed unpaired Welch's t-test assuming unequal variances, unless otherwise stated. The distribution of datasets were tested for normality using the Shapiro–Wilks test and through the generation of quantile–quantile (Q–Q) plots. Graphical representations of data showing individual values within a group include a vertical error bar line, denoting SD, and a horizontal line denoting mean value. Data were analyzed with the JMP Pro (Version14, JMP Statistical Discovery, LLC) statistical software. Visualization of data in the form of figures was completed using GraphPad Prism (Version 9.3.0, GraphPad Software, LLC).

Role of the funding source

The funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Results

Single-cell RNA-seq study to profile human colonic Mucosa in obesity

We previously described a workflow for the cryopreservation of endoscopically obtained human intestinal mucosal biopsies, subsequent preparation of this tissue to yield highly viable FACS-isolated human intestinal single-cell suspensions compatible with successful library preparation and deep scRNA-Seq.19 Using this workflow, we performed scRNA-Seq using the 10X Genomics platform on live FACS-isolated cell samples derived from cryopreserved colonic mucosal biopsies in a single batch. Samples were obtained from 5 participants with obesity [(mean ± SD): age 44 ± 4.9 years old, BMI 35.4 ± 2.1 kg/m2, 80% females] and 4 lean (healthy weight controls) participants [(mean ± SD): age 28 ± 1.4 years old, BMI 23 ± 2.9 kg/m2, 75% females] (Table 1, “scRNA-Seq”). Following data filtering we analyzed the transcriptomes of an estimated 16,723 single cells of the human gut mucosa, and detected an average of 24,000 genes, 89% mapping to the genome, and in total, 705 million reads, at 127,000 reads per cell.

Human colonic Mucosa clusters into 20 subsets and identifies an enteroendocrine subset

A clustering analysis of the human colon partitioned cells into 20 transcriptionally distinct subsets (Supplemental Figure S1a). The EEC cluster was identified by conserved expression of Chromogranin A (CgA), a hallmark for gut EECs.6,31,32 The major classically defined EEC subsets present in the human colon were identified as 5HT-expressing EC cells (TPH1), GLP-1 (GCG) and PYY-expressing L cells, SST-expressing D cells (Supplemental Figure S1b and c). A total of 117 EECs were identified comprising approximately 0.75% of the total gut mucosa. The EEC cluster comprised an estimated 0.8% (77 cells), and 0.7% (40 cells) of the total mucosal population in lean and obesity, respectively, and no significant difference in mean ratio of EECs was detected between the groups.

Transcriptomic RGS profile of human EECs and alterations in obesity

We next investigated the RGS transcriptomic profile of native human intestinal EECs from jejunum and colon. Expression of 12 RGS genes were detected in EECs (Fig. 1a). Among GCG-expressing EECs, classically defined as L-type EECs, RGS9, followed by RGS12, were the most highly expressed RGS genes in the colon, whereas RGS2 followed by RGS4 was mostly highly expressed in jejunum. In the EECs without GCG expression, referred to as non-L-type EECs, RGS2, followed by RGS9 were the most highly expressed in the colon; and RGS2 and RGS12 were the mostly highly expressed in jejunum. Expression of RGS4, RGS7, RGS9, RGS11, and RGS12 was enriched in both colonic and jejunal L-type EECs compared to non-EECs (Fig. 1b). Within EECs, Expression of RGS14, RGS7, RGS10, RGS12, and RGS9 was enriched in L-type EECs compared to non-L-type EECs in colon (Fig. 1c). However, in jejunum enrichment of RGS14, RGS9, RGS4, RGS11, RGS1, RGS3 and RGS19 expression was observed in L-type EECs compared to non-L-type EECs. While expression of many RGS genes were detected in EECs, only RGS2 and RGS9 were expressed in the majority proportion (>0.50) of colonic all-EECs (0.66 and 0.70, respectively) (Fig. 1d). RGS9 and RGS7, represented the RGS genes displaying expression in a majority proportion of colonic L-type EECs (0.76, 0.50, respectively); similar to all-EECs, RGS9 was again expressed in the greatest proportion of L-type EECs (Fig. 1e).Fig. 1 Transcriptomic profiling of the RGS family in intestinal human EECs and alterations in obesity a) mRNA Expression levels of RGS family genes within three defined cell types: L-type EECs (red bars), non-L-type EECs (blue bars) and non EECs (green bars) in the human colon profiled from the present scRNAseq study (striped bars), and human jejunum profiled from previous a RNAseq study from Roberts et al., 2019 (solid bars). Fold-Enrichment values of RGS family mRNA expression within b) L-type EECs compared to non-L-type EECs and c) L-type EECs compared to non-EECs in human colon profiled from the present scRNAseq study (red bars), and human jejunum profiled from previous a RNAseq study from Roberts et al., 2019 (blue bars). The average proportion of d) all colon EECs within cluster or e) L-type cells within EECs expressing detected RGS family genes. f) RGS family genes demonstrating differential expression in all EECs within cluster for obesity compared to lean. Bar charts display the Mean value for respective data. Error bar lines denote SD. # denotes physiologically relevant finding defined as RGS genes displaying differential Log2FC in obesity with p < 0.20 in either all EECs or L-type EECs.

We next explored transcriptional alterations to RGS expression within colonic EECs in the context of obesity. We considered physiologically relevant hits as RGS genes displaying differential Log2FC in obesity with p < 0.20 in either all EECs or L-type EECs. Using this criteria RGS2, RGS4, RGS9, and RGS12 were identified as having physiologically relevant transcriptional alterations in obesity compared to lean (Fig. 1f) (Supplemental Table S2). In all-EECs RGS12 displayed significantly increased expression in obesity (0.31 Log2FC, p = 0.0019), and a trend of increased expression in L-type EECs (Log2FC = 0.32, p = 0.20). A trend of increased RGS9 expression was demonstrated in both all-EECs and L-type EECs in obesity compared to lean (Log2FC = 0.29, p = 0.19, Log2FC = 0.61, p = 0.10, respectively). In contrast, Both RGS2, and RGS4 displayed significant decreased expression in all-EECs in obesity (−0.75 Log2FC, p = 0.043; −0.42 Log2FC, p = 0.012, respectively). Unlike RGS9 and RGS12, alterations to RGS2 and RGS4 in all-EECs were not mirrored in L-type EECs.

Intestinal RGS profile association with obesity status and BMI

In two validation cohorts we aimed to confirm the NGS findings of RGS expression in human intestine and further corroborate trends in differential RGS expression in obesity. In the first validation cohort (Table 1, “Single-cell RGS Family Tissue Validation”), we confirmed gut expression of RGS in both human ileum and colon in 15 participants. Expression of RGS2, RGS11, and RGS14 was higher in the human ileum than colon, whereas expression levels of RGS4, RGS9, RGS12, and RGS17 were similar (Supplemental Figure S2). In a second validation cohort (Table 1, “Colonic RGS Hormone Associations”) we sought to confirm our scRNAseq findings with respect to alterations in colonic RGS2, RGS4, RGS9, and RGS12 in the context of obesity as both a categorical and quantitative variable in 16 lean healthy control patients and 31 patients with obesity. While the single-cell data set identified RGS2, RGS4, RGS9, and RGS12 as having physiologically relevant transcriptional alterations within EECs in obesity, this finding was only validated for RGS9 in the colon. Colonic RGS9 demonstrated significant overexpression in obesity compared to lean (0.0033 ± 3.9e-004 vs. 0.0012 ± 2.1e-004, respectively; mean difference 0.002142 [95% CI 0.001250–0.003035], Log2FC = 1.50; p < 0.0001) (Fig. 2a). Protein expression of colonic RGS9 was additionally confirmed to be overexpressed in obesity (n = 10), compared to lean (n = 9) (1.23 ± 0.28 vs. 0.99 ± 0.11, respectively, mean difference 0.24 [95% CI 0.035–0.45], Log2FC = 0.30, p = 0.026) (Supplemental Figure S3). Colonic expression of RGS2, RGS4, and RGS12 in obesity was not significantly different compared to lean. Assessment of RGS with respect to BMI also revealed a significant positive association with colonic RGS9 (r = 0.66 (0.44–0.80); p < 0.0001); expression levels of RGS2, RGS4, and RGS12 were not found to be associated with BMI (Fig. 2b–e). We further confirmed expression at the protein level in CgA-expressing human EECs in RGS2, RGS4, RGS9, and RGS12 in human colon, and ileum (Fig. 3). Protein expression of RGS4 remained detectable, yet low in human intestine, consistent with validation mRNA expression data.Fig. 2 Validation of the colonic enteroendocrine cell RGS profile and its intestinal transcriptomic alterations in obesity. a) colonic RGS expression comparing lean (green triangle, n = 16 total cohort) and obesity (purple diamonds, n = 31 total cohort). Associations of BMI (kg/m2) with colonic mRNA expression of b)RGS2c)RGS4d)RGS9, and e)RGS12. Significance testing used a two-tailed unpaired Welch's t-test to compare between lean and obesity; data showing individual values within a group include a vertical error bar line, denoting SD, and a horizontal line denoting Mean value. The Spearman rank correlation analysis quantified the relationship between respective RGS expression and BMI. Spearman's correlation coefficient (r) is reported with 95% CI.

Fig. 3 Validation of RGS Expression in Human Intestinal Tissue. Immunofluorescence (IF) staining of human mucosal colonic and ileal tissue sections demonstrating coexpression of RGS (green) with CgA (pink); red bar indicates 10 μm, nuclei stained with DAPI (Blue). 40x water Immersion objective.

Intestinal RGS association with GLP-1 and PYY expression and postprandial response

We next sought to determine the relationship between RGS and L-type EEC functionality in the context of GLP-1 and PYY mRNA expression and their respective postprandial blood levels in human subjects from the second validation cohort of 47 participants with colonic biopsies, 34 of which also had postprandial plasma GLP-1 and PYY. Colonic RGS2 mRNA expression was positively associated with colonic GCG mRNA expression (r = 0.50 (0.23–0.70); p = 0.00040), and PYY mRNA expression (r = 0.29 (−0.01 to 0.54); p = 0.048) but not post prandial GLP-1 or PYY levels (Fig. 4a–d). Colonic RGS4 mRNA expression was positively associated with both postprandial GLP-1 AUC0–90 min (r = 0.35 (−0.002 to 0.62); p = 0.045) and colonic GCG mRNA expression (r = 0.60 (0.37–0.76); p < 0.0001), but not PYY colonic expression or postprandial levels (Fig. 4e–h). After ingestion of a meal, intestinal RGS9 level was inversely associated with plasma post-prandial GLP-1 AUC0–90 min (r = −0.45 (−0.69 to 0.12); p = 0.0075); but expression of GCG mRNA was not associated with RGS9 mRNA (Fig. 4i–j). Similar to GLP-1, RGS9 expression was also inversely associated with plasma post-prandial PYY AUC0–90 min (r = −0.46 (−0.69 to 0.15); p = 0.0043), and further inversely associated colonic PYY mRNA expression (r = −0.34 (−0.58 to 0.05); p = 0.022) (Fig. 4k–l). A significant negative association was observed between RGS12 mRNA expression and postprandial GLP-1 AUC0–90 min (r = −0.51 (−0.73 to 0.17); p = 0.0038) (Fig. 4m). No associations were observed between RGS12 and GCG or PYY mRNA expression or postprandial PYY blood levels (Fig. 4n–p).Fig. 4 Correlation of colonic RGS expression and satiety hormones. mRNA Expression of colonic RGS2 associations with area under the curve (AUC) for plasma concentrations of a) GLP-1, and c) PYY for time points 0–90 min postprandial (n = 34), and colonic expression of b)GCG and d)PYY mRNA (n = 47). mRNA Expression of colonic RGS4 associations with AUC 0-90 mins for plasma concentrations of e) GLP-1, and g) PYY and colonic expression of f)GCG and h)PYY mRNA. mRNA Expression of colonic RGS9 associations with AUC 0-90 mins for plasma concentrations of i) GLP-1, and k) PYY and colonic expression of j)GCG and l)PYY mRNA. mRNA Expression of colonic RGS12 associations with AUC 0-90 mins for plasma concentrations of m) GLP-1, and o) PYY and colonic expression of n)GCG and p)PYY mRNA. Cohort of 47 participants with colonic biopsies, 34 of which also had postprandial plasma GLP-1 and PYY. Significance testing used the Spearman rank correlation test to quantify the relationship between the two tested variables in each panel. Spearman's correlation coefficient (r) is reported with 95% CI.

RGS inhibition modulates GPCR-mediated GLP-1 and release in human ex vivo cultures

To investigate the consequences of RGS-alterations on GLP-1 hormone release, primary human intestinal monolayer cultures, originating from human colon and ileal tissue were exposed to a nonselective inhibitor of RGS activity, CCG-50014, at 3 doses (2.5, 25, 250 μM). Compared to control media, 2-h treatment of ex vivo tissue with 25 μM CCG-50014 increased the secretion of GLP-1 into the media approximately 2.02 ± 0.44-fold in terminal ileum (mean difference 1.02 [95% CI 0.46–1.57], p = 0.0042) and 1.29 ± 0.17-fold in colon (mean difference 0.29 [95% CI 0.098–0.48], p = 0.0078) (Fig. 5a). Additionally, treatment with 250 μM CCG-50014 in terminal ileum, but not colon potentiated secretion of GLP-1 compared to control (2.85 ± 1.06-fold change, mean difference 1.85 [95% CI 0.74–2.97], p = 0.0075).Fig. 5 Human gut RGS and functional relation to GPCR-mediated hormone secretion. a) Primary cultures of human terminal ileum and colon were treated for 2 h with increasing doses of the nonspecific RGS inhibitor CCG-50014 and measured for secretion of GLP-1 into the media. b) Primary cultures of human terminal ileum were treated with known satiety hormone secretagogues (2% meat hydrolysate, 500 μM 1,10-Phenanthroline, 500 μM sodium acetate) in the presence or absence of 25 μM CCG-50014 and measured for secretion of GLP-1. Data expressed as fold-change to the respective controls. Data showing individual values within a group include a vertical error bar line, denoting SD, and a horizontal line denoting Mean value. Significance testing used a two-tailed unpaired Welch's t-test to compare between signified groups.

We next explored how RGS inhibition would affect hormone response from EECs when used in conjunction with known GLP-1 secretagogue GPCR-agonists: bitter tastant 1,10-Phenanthroline (1,10-PA) targeting Taste 2 Receptor 5 (T2R5); short chain fatty acids acetate and propionate targeting GPR41/43; taurocholic acid (TCA) a bile acid targeting TGR5; and 2% meat hydrolysate (2% MH) targeting GPR93/CASR. Treatment of ex vivo human intestinal tissue with these agents potentiated the secretion of GLP-1 from human intestinal tissue compared with control (p < 0.05 all) (Fig. 5b). Secretion of GLP-1 was further augmented by the addition of CCG-50014 (25 μM) in conjunction with 1,10-PA and TCA (1.84 ± 0.31-fold, 1,10-PA + CCG-50014 vs. 1.42 ± 0.27-fold, 1,10-PA alone, mean difference 0.42 [95% CI 0.019–0.82], p = 0.042; 1.76 ± 0.07-fold TCA + CCG-50014 vs. 1.45 ± 0.19-fold, TCA alone, mean difference 0.31 [95% CI 0.11–0.51], p = 0.0082). Interestingly, the GLP-1 secretory effect of 2%MH was significantly dampened by the addition of the RGS inhibitor (1.37 ± 0.21-fold 2%MH + CCG-50014 vs. 1.69 ± 0.24-fold 2%MH alone, mean difference −0.33 [95% CI −0.62 to −0.033], p = 0.033), yet GLP-1 levels remained elevated compared to control (1.37 ± 0.21-fold 2%MH + CCG-50014 vs. 1.00 ± 0.06-fold, control, mean difference 0.37 [95% CI 0.15–0.59], p = 0.0070). Acetate/Propionate-stimulated GLP-1 secretion was not significantly altered by addition of RGS inhibitor.

RGS9 overexpression modulates GPCR-mediated GLP-1 secretion in vitro

We further explored how RGS may influence GPCR-mediated secretion of GLP-1 from a human model of L-type EECs. First, we overexpressed RGS9 in NCI–H716 cells (H716RGS9) (Fig. 6a and b), a nutrient-responsive human in vitro model of L-type EECs cells capable of secreting GLP-1 upon differentiation.15,27 Secretion of GLP-1 with vehicle control was significantly blunted in H716RGS9 with levels dampened by 56% compared to wild-type NCI–H716 (H716WT) (H716WT vehicle, 1.00 ± 0.012 vs. H716RGS9 vehicle, 0.44 ± 0.11; mean difference −0.56 [95% CI −0.67 to −0.45], p < 0.0001) (Fig. 6c). Unlike ex vivo human intestinal cells, treatment with CCG-50014 (25 μM) alone was not sufficient to potentiate the secretion of GLP-1 from either the H716WT or H716RGS9 compared to their respective vehicle controls. While both H716WT and H716RGS9 appropriately responded to stimulation with bitter tastant GPCR-agonist 1,10-PA (1 mM) exposure with subsequent increased secretion of GLP-1 compared to their vehicle controls, H716RGS9 GLP-1 secretory response was blunted compared to H716WT (1,10-PA vs. respective vehicle: H716WT 2.18 ± 0.96-fold increase, mean difference 1.18 [95% CI 0.49–1.87] p = 0.0036; H716RGS9 1.41 ± 0.22-fold increase, mean difference 0.18 [95% CI 0.083–0.28], p = 0.0012; ΔGLP-1 to 1,10-PA: H716WT vs. H716RGS9 p = 0.033). Supplementation of CCG-50014 (25 μM) to 1,10-PA treatment further potentiated GLP-1 secretion an additional 1.5-fold in H716WT (1,10-PA, 2.18 ± 0.96-fold increase vs. 1,10-PA + CCG-50014, 3.27 ± 1.22-fold increase; mean difference 1.09 [95% CI 0.059–2.13], p = 0.040), and compared to vehicle control GLP-1 secretion heighted 3.27-fold (1,10-PA + CCG-50014, 3.27 ± 1.22-fold increase vs. control, 1.00 ± 0.12; mean difference 2.27 [95% CI 1.40–3.15], p = 0.00022). Secretory GLP-1 response in H716RGS9 was also heightened with supplementation of CCG-50114 to the 1,10-PA treatment with GLP-1 increased 3.06-fold compared to respective vehicle control, (1,10-PA + CCG-50014, 1.33 ± 0.43 vs. vehicle, 0.44 ± 0.11; mean difference 0.89 [95% CI 0.58–1.20], p < 0.0001), and 2.1-fold compared to 1,10-PA treatment alone (1,10-PA + CCG-50014, 1.33 ± 0.43 vs. 1,10-PA, 0.62 ± 0.10; mean difference 0.71 [95% CI 0.40–1.02], p = 0.00045). However, GLP-1 levels for all treatments were significantly decreased in H716RGS9 compared to their respective treatments in H716WT (p < 0.001, all).Fig. 6 NCI–H716 transgenic line overexpressing RGS9 and GPCR-mediated hormone secretion. a) Relative mRNA, measured by RT-qPCR and protein expression using b) Western blot and of RGS9 in wild-type (H716WT) or RGS9 overexpressing H716 cells (H716RGS9). c) GLP-1 secretion from H716WT and H716RGS9 cells treated for 2 h without and with CCG-50014 in response to 1,10 Phenanthroline (1 mM), compared to vehicle control (DPBS). Data expressed as normalized to protein content, and as fold-change to the wild-type control. Data showing individual values within a group include a vertical error bar line, denoting SD, and a horizontal line denoting Mean value. Significance testing used a two-tailed unpaired Welch's t-test to compare between signified groups among respective cells. Significance testing used a two-tailed unpaired Welch's t-test to compare GLP-1 between wild-type and H716RGS9 for respective treatments ###p < 0.001.

Discussion

The gut L-type EECs secrete satiety-inducing hormones GLP-1 and PYY after a meal in response to activation of their surface GPCRs by luminal components of nutrient digestion and microbial fermentation. The RGS family of GTPase-activating proteins (GAPs) are major negative regulators of GPCRs through their ability to rapidly induce GPCR signal termination. Prior to this study, RGS had yet to be directly investigated in EECs. In the present work, we identified and validated the expression of the RGS family of proteins in gut EECs and demonstrated their altered expression profile in obesity. Furthermore, RGS may modulate secretion of satiety hormones GLP-1 and PYY from EECs, and alterations to their expression may promote aberrant nutrient-mediated GPCR signaling.

The RGS family of proteins accelerate hydrolysis of the active GTP-bound Gα to the inactive GDP-bound Gα, effectively leading to the rapid termination of GPCR signaling.16 As these proteins represent a major mechanism for the negative regulation of GPCR signaling, we hypothesized that EECs, which rely heavily on chemosensory GPCRs, employ RGS proteins to coordinate the intricate balance between signaling activation and deactivation within the cell. Indeed, our transcriptomic profiling of human colonic enteroendocrine cells using scRNA-Seq and our analysis of a publicly available dataset profiling human jejunal enteroendocrine cells using RNAseq (GSE114853), demonstrated the expression of a unique set of RGS genes in human EECs of the colon and jejunum. A wide range of expression was displayed among the RGS family and appeared tissue- and cell type-specific. While expression of RGS2 showed the highest overall expression in both colon and jejunum, it was not enriched in L-type EECs; furthermore, its colonic expression was limited to a minority of colonic L-type EECs. RGS4, RGS7, RGS9, RGS11, and RGS12 were enriched in L-cells compared to non-EEC mucosal cells in both colon and jejunum, whereas among EECs, L-cell enrichment in both tissues was only observed in RGS4, RGS9, and RGS14.

Previous studies have associated tissue specific and global RGS alterations with human disease states including obesity.17,18 Here, we show in colonic EECs, obesity was associated with an altered RGS profile, with differential expression patterns in colonic RGS2 (underexpression), RGS4 (underexpression), RGS9 (overexpression), and RGS12 (overexpression). Overexpression of whole colonic RGS9 in obesity was further validated in whole human colonic mucosa and additionally associated with BMI.

We next aimed to characterize the functional role of RGS proteins in L-type EEC-dependent hormone secretion. The production and secretion of GLP-1 and PYY from human EECs in vivo can be indirectly studied by evaluating their fasting mRNA expression and concentrations in blood plasma in the fasting and postprandial state.33, 34, 35 Here we report that colonic RGS2, RGS4, RGS9, and RGS12 may be of importance to human EEC functionality in regards to hormone production and or secretion, as evidenced by their associations with mRNA expression or postprandial plasma levels of GLP-1 and PYY.

Importantly, RGS9 expression displayed negative correlations with plasma concentrations of postprandial satiety hormones, in addition to its positive correlation with BMI. Overexpression of RGS9 in an in vitro model of human L-type EECs was associated with blunted nutrient-stimulated GLP-1 secretion that was improved but not fully rescued upon administration of a non-selective RGS inhibitor in conjunction with a GLP-1 secretagogue. The non-selective inhibition of intestinal RGS potentiated the secretion of GLP-1 in ex vivo human intestinal tissue. Additionally, the GLP-1 secretory responses mediated by stimulation with GLP-1 secretagogue GPCR-agonists 1,10-PA (targeting bitter taste receptor T2R5) and TCA (targeting bile acid receptor TGR5) were further augmented with RGS inhibition in ex vivo human intestinal tissue. However, GLP-1 responses mediated through short chain fatty acid receptor activation with acetate/propionate were unaffected by RGS inhibition, and negatively affected with 2% MH-mediated stimulation of amino acid/peptide receptors. These differential GLP-1 secretory responses observed between the GLP-1 secretagogue GPCR-agonists are likely reflected by the selectivity of RGS proteins for Gα subunits of heterotrimeric G-proteins.36 A comprehensive understanding of the α-subunit linkage of relevant EEC nutrient sensing GPCRs coupled with current knowledge of RGS-Gα selectivity will be crucial for future studies aiming to dissect the dynamic relationship between RGS and their associated GPCRs in EECs and harness their potential to modulate GLP-1 secretion. While these data suggest an association between RGS, RGS9, and L cell hormone products, further studies are required to determine the exact mechanistic relationship between relevant RGS proteins and L cell functionality.

In the context of obesity the secretion of GI hormones may be impaired, as attenuated postprandial levels of GLP-1 and PYY have been characterized in some studies of obesity and negatively associated with appetite, length of postprandial satiety, and energy intake.8,10,33,37, 38, 39, 40 In the present study we show intestinal RGS expression is altered in obesity and associated with postprandial GLP-1 and PYY. However, In our cohorts fasting and postprandial GLP-1 and PYY were not altered in obesity; therefore, it is unlikely overexpression of RGS9 represents a universal pathophysiological process in obesity. However, phenotypic subgroups of obesity characterized by abnormal postprandial satiety hormone responses have been reported, and investigating RGS function in such patients could illuminate a pathophysiologic process.41

Many pharmacological attempts have been made to simulate the physiological effects of L-cell satiety hormone peptides GLP-1 and PYY as a treatment for obesity,1,5 and the findings presented in the current manuscript indicate that consideration of EEC-specific RGS may present new beneficial applications to therapeutic strategies in GPCR-based drug discovery for obesity. The RGS family, specifically RGS9, may serve as novel targets for the modulation of satiety hormone secretion in obesity. Additionally, our study indicates that even in the presence of a potent small molecule GLP-1/PYY secretagogue, there still may exist an intracellular signaling blockade, mediated by altered RGS expression, preventing full secretion potential. Thus, a powerful and potentially necessary pharmacological approach to stimulating maximal endogenous secretion of these satiety hormones may include the combination of GPCR agonists coupled with EEC-specific RGS inhibitors.

It is important to note some limitations of our investigation. First, transcriptomic profiling was completed in human jejunal and colonic EECs, while validation and further studies included human ileal and colonic tissue. Controversy remains regarding the significance of colonic EECs and GLP-1 from colonic origins on food intake, and potential differences in nutrient-stimulated responses between L-type EECs originating from colon and small intestine.42 However, EECs are distributed throughout the GI tract, the concentrations of GLP-1 and PYY are similar in the ileum and colon,43,44 and the current literature describes colonic EECs, similar to their ileal and jejunal counterparts, capable of influencing postprandial plasma hormone responses.45,46 Second, the initial discovery cohort studied EEC-specific RGS, whereas the validation cohorts utilized whole tissue and therefore were not specific to EECs. Further studies in isolated populations of EECs will be important. Third, our functional ex vivo and in vitro studies utilized a nonselective RGS inhibitor, therefore we cannot fully conclude a role for specific RGS proteins. Finally, the experimental design of our studies did not control for confounding effects, which may have biased the study results. Detailed mechanistic studies will be important to further elucidate the role of RGS proteins in enteroendocrine cell physiology.

This study introduces RGS proteins as likely regulators of satiety hormone secretion from EECs. Alterations in gut RGS levels may play a role in EEC pathophysiological processes and could represent novel therapeutic targets in obesity.

Contributors

All authors read and approved the final version of the manuscript. Individual contributions to the manuscript were: Conceptualization, AM and AA; Methodology, AM, AT, VS, YL, and AA; Validation, AM, AT, NM, FFJ and MRS; Formal Analysis, AM, YL, YL, and AA; Investigation, AM, MRS, AT, YL, YL, FFJ, DGI, GC, FR, VS, DG, CL and AA; Writing—Original Draft: AM and AA. Writing—Review & Editing, AM, AT, MRS, NM, FFJ, DGI, GC, FR, YL, YL, VS, CL, DH, NL and AA; Visualization, AM, YL, MRS, and AA; Supervision, YL, NL and AA; Project Administration, AM and AA; Funding Acquisition, AM and AA.

Data sharing statement

Data collected for the study, including individual de-identified participant data, as well as the study protocol and informed consent will be available to interested parties with publication after signing of a data access agreement. Data may be requested by contacting Dr. Andres Acosta M.D, Ph.D., at acosta.andres@mayo.edu. Partial sequencing data generated during this study are included in this published article and its supplemental information files. Full data is publicly available from the Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information (NCBI) repository under accession number: GSE154405.

Declaration of interests

AA is a stockholder in Gila Therapeutics, Phenomix Sciences. AA provides consulting services for Rhythm Pharmaceuticals, General Mills, Amgen, RareStone, and Bausch Health. DH provides consulting services for Novo Nordisk and receives presentation compensation from the Obesity Medicine Association and The Menopause Society.

Appendix A Supplementary data

Supplementary Material

WB BACT Original.png

WB RGS9 Original.png

Acknowledgements

This study was supported by the NIH (C-Sig P30DK84567) and NIDDK K23 DK114460 award (AA), a Pilot Award from the Mayo Clinic Center for Biomedical Discovery (AA), and the Translational Product Development Fund from The Mayo Clinic Center for Clinical and Translational Science Office of Translational Practice in partnership with the 10.13039/100018188 University of Minnesota Clinical and Translational Science Institute (AA). NL is supported by NIH R01 DK57993, NIH R01 DK24031, NIH P30 DK84567, NIH P30 DK90728, NIH R01 DK117133. DH is supported by NIH K12AR084222 and Phenomix Sciences. We thank participants in the studies, the nurses and staff of the Mayo Clinic Clinical Research Unit, and the Mayo Clinic Gastrointestinal Endoscopy Units for nursing support and the care of patients. The study was conducted in the clinical research unit and the Mayo Clinic Gastrointestinal Endoscopy Unit.

Appendix A Supplementary data related to this article can be found at https://doi.org/10.1016/j.ebiom.2024.105283.
==== Refs
References

1 Gribble F.M. Reimann F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism Nat Rev Endocrinol 15 4 2019 226 237 30760847
2 Gribble F.M. Reimann F. Enteroendocrine cells: chemosensors in the intestinal epithelium Annu Rev Physiol 78 2016 277 299 26442437
3 Beumer J. Artegiani B. Post Y. Enteroendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient Nat Cell Biol 20 8 2018 909 916 30038251
4 Haber A.L. Biton M. Rogel N. A single-cell survey of the small intestinal epithelium Nature 551 7680 2017 333 339 29144463
5 Mace O.J. Tehan B. Marshall F. Pharmacology and physiology of gastrointestinal enteroendocrine cells Pharmacol Res Perspect 3 4 2015 e00155
6 Rindi G. Leiter A.B. Kopin A.S. Bordi C. Solcia E. The "normal" endocrine cell of the gut: changing concepts and new evidences Ann N Y Acad Sci 1014 2004 1 12 15153415
7 Reimann F. Tolhurst G. Gribble F.M. G-protein-coupled receptors in intestinal chemosensation Cell Metab 15 4 2012 421 431 22482725
8 Batterham R.L. Cohen M.A. Ellis S.M. Inhibition of food intake in obese subjects by peptide YY3-36 N Engl J Med 349 10 2003 941 948 12954742
9 Faerch K. Torekov S.S. Vistisen D. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study Diabetes 64 7 2015 2513 2525 25677912
10 Ranganath L.R. Beety J.M. Morgan L.M. Wright J.W. Howland R. Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38 6 1996 916 919 8984033
11 Verdich C. Toubro S. Buemann B. Lysgard Madsen J. Juul Holst J. Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction Int J Obes Relat Metab Disord 25 8 2001 1206 1214 11477506
12 Sumithran P. Prendergast L.A. Delbridge E. Long-term persistence of hormonal adaptations to weight loss N Engl J Med 365 17 2011 1597 1604 22029981
13 Jorgensen N.B. Jacobsen S.H. Dirksen C. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance Am J Physiol Endocrinol Metab 303 1 2012 E122 E131 22535748
14 Nauck M.A. Quast D.R. Wefers J. Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art Mol Metab 46 2021 101102
15 de Bruine A.P. Dinjens W.N. van der Linden E.P. Pijls M.M. Moerkerk P.T. Bosman F.T. Extracellular matrix components induce endocrine differentiation in vitro in NCI-H716 cells Am J Pathol 142 3 1993 773 782 8456938
16 Watson N. Linder M.E. Druey K.M. Kehrl J.H. Blumer K.J. RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits Nature 383 6596 1996 172 175 8774882
17 Squires K.E. Montanez-Miranda C. Pandya R.R. Torres M.P. Hepler J.R. Genetic analysis of rare human variants of regulators of G protein signaling proteins and their role in human physiology and disease Pharmacol Rev 70 3 2018 446 474 29871944
18 Waugh J.L. Celver J. Sharma M. Association between regulator of G protein signaling 9-2 and body weight PLoS One 6 11 2011 e27984
19 McRae A. Ricardo-Silgado M.L. Liu Y. A protocol for the cryopreservation of human intestinal Mucosal biopsies compatible with single-cell transcriptomics and ex vivo studies Front Physiol 13 2022
20 Robinson M.D. McCarthy D.J. Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data Bioinformatics 26 1 2010 139 140 19910308
21 Roberts G.P. Larraufie P. Richards P. Comparison of human and murine enteroendocrine cells by transcriptomic and peptidomic profiling Diabetes 68 5 2019 1062 1072 30733330
22 Ersahin T. Carkacioglu L. Can T. Konu O. Atalay V. Cetin-Atalay R. Identification of novel reference genes based on MeSH categories PLoS One 9 3 2014 e93341
23 Eissa N. Hussein H. Wang H. Rabbi M.F. Bernstein C.N. Ghia J.E. Stability of reference genes for messenger RNA quantification by real-time PCR in mouse dextran sodium sulfate experimental colitis PLoS One 11 5 2016 e0156289
24 Reimann F. Habib A.M. Tolhurst G. Parker H.E. Rogers G.J. Gribble F.M. Glucose sensing in L cells: a primary cell study Cell Metab 8 6 2008 532 539 19041768
25 Psichas A. Tolhurst G. Brighton C.A. Gribble F.M. Reimann F. Mixed primary cultures of murine small intestine intended for the study of gut hormone secretion and live cell imaging of enteroendocrine cells J Vis Exp 122 2017
26 Park J. Kim K.S. Kim K.H. GLP-1 secretion is stimulated by 1,10-phenanthroline via colocalized T2R5 signal transduction in human enteroendocrine L cell Biochem Biophys Res Commun 468 1-2 2015 306 311 26505793
27 Reimer R.A. Darimont C. Gremlich S. Nicolas-Metral V. Ruegg U.T. Mace K. A human cellular model for studying the regulation of glucagon-like peptide-1 secretion Endocrinology 142 10 2001 4522 4528 11564718
28 Tolhurst G. Heffron H. Lam Y.S. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2 Diabetes 61 2 2012 364 371 22190648
29 Wu T. Bound M.J. Standfield S.D. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans Diabetes Obes Metab 15 5 2013 474 477 23181598
30 Hayes M.P. Bodle C.R. Roman D.L. Evaluation of the selectivity and cysteine dependence of inhibitors across the regulator of G protein-signaling family Mol Pharmacol 93 1 2018 25 35 29051318
31 O'Connor D.T. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum Regul Pept 6 3 1983 263 280 6622754
32 O'Connor D.T. Burton D. Deftos L.J. Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands Life Sci 33 17 1983 1657 1663 6633161
33 Gibbons C. Caudwell P. Finlayson G. Comparison of postprandial profiles of ghrelin, active GLP-1, and total PYY to meals varying in fat and carbohydrate and their association with hunger and the phases of satiety J Clin Endocrinol Metab 98 5 2013 E847 E855 23509106
34 Elliott R.M. Morgan L.M. Tredger J.A. Deacon S. Wright J. Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns J Endocrinol 138 1 1993 159 166 7852887
35 Deacon C.F. What do we know about the secretion and degradation of incretin hormones? Regul Pept 128 2 2005 117 124 15780431
36 Masuho I. Balaji S. Muntean B.S. A global map of G protein signaling regulation by RGS proteins Cell 183 2 2020 503 521.e19 33007266
37 Naslund E. Gutniak M. Skogar S. Rossner S. Hellstrom P.M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men Am J Clin Nutr 68 3 1998 525 530 9734726
38 Naslund E. Barkeling B. King N. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men Int J Obes Relat Metab Disord 23 3 1999 304 311 10193877
39 Gibbons C. Hopkins M. Beaulieu K. Oustric P. Blundell J.E. Issues in measuring and interpreting human appetite (Satiety/Satiation) and its contribution to obesity Curr Obes Rep 8 2 2019 77 87 31037612
40 Stock S. Leichner P. Wong A.C. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents J Clin Endocrinol Metab 90 4 2005 2161 2168 15657373
41 Acosta A. Camilleri M. Shin A. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy Gastroenterology 148 3 2015 537 546.e4 25486131
42 Richards P. Pais R. Habib A.M. High fat diet impairs the function of glucagon-like peptide-1 producing L-cells Peptides 77 2016 21 27 26145551
43 Jorsal T. Rhee N.A. Pedersen J. Enteroendocrine K and L cells in healthy and type 2 diabetic individuals Diabetologia 61 2 2018 284 294 28956082
44 Adrian T.E. Ferri G.L. Bacarese-Hamilton A.J. Fuessl H.S. Polak J.M. Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY Gastroenterology 89 5 1985 1070 1077 3840109
45 van Battum P.L. Hopman W.P. Salemans J.M. Kuijpers J.H. Nagengast F.M. Jansen J.B. Impaired release of peptide YY in patients with proctocolectomy and ileal pouch-anal anastomosis Scand J Gastroenterol 34 4 1999 404 408 10365901
46 Adrian T.E. Gariballa S. Parekh K.A. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers Diabetologia 55 9 2012 2343 2347 22696033
